| Market Capitalization (Millions $) |
4,482 |
| Shares
Outstanding (Millions) |
82 |
| Employees |
56 |
| Revenues (TTM) (Millions $) |
- |
| Net Income (TTM) (Millions $) |
-293 |
| Cash Flow (TTM) (Millions $) |
-140 |
| Capital Exp. (TTM) (Millions $) |
0 |
Business Description
Akero Therapeutics Inc. is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for serious metabolic diseases. It was founded in 2017 and is headquartered in South San Francisco, California. The company's lead product candidate, Efruxifermin (EFX), is an engineered analog of fibroblast growth factor 21 (FGF21), a key regulator of metabolism that controls glucose, energy, and lipid homeostasis.
EFX is being developed for the treatment of nonalcoholic steatohepatitis (NASH), a chronic liver disease characterized by fat accumulation in the liver, inflammation, and fibrosis. NASH is a growing public health concern with no approved treatments available. EFX has the potential to address the underlying metabolic dysfunction in NASH patients and reduce liver fat, inflammation, and fibrosis, thereby improving liver and overall metabolic health.
Akero Therapeutics has completed several clinical trials of EFX, including a Phase 2a clinical trial in NASH patients, which showed promising results. The company has also initiated a Phase 2b clinical trial in NASH patients, which is currently ongoing.
In addition to NASH, Akero Therapeutics is exploring the potential of EFX in other metabolic diseases, such as type 2 diabetes and obesity. The company is also conducting research on other FGF analogs and their potential applications in metabolic diseases.
Akero Therapeutics is led by a team of experienced biotech executives and researchers with a proven track record of developing and commercializing successful therapies. The company has formed strategic partnerships with industry leaders, including Amgen and Atlas Venture, to advance the development of EFX and other product candidates.
Overall, Akero Therapeutics is a promising biotech company with a potentially transformative therapy for NASH and other metabolic diseases. The company's innovative approach and experienced leadership team make it an exciting company to watch in the biopharmaceutical industry.
Company Address: 601 Gateway Boulevard, Suite 350 South San Francisco 94080 CA
Company Phone Number: 487-6488 Stock Exchange / Ticker: NASDAQ AKRO
|
0.24% 